D
Drosos E. Karageorgopoulos
Researcher at ALFA
Publications - 96
Citations - 8856
Drosos E. Karageorgopoulos is an academic researcher from ALFA. The author has contributed to research in topics: Fosfomycin & Antibacterial agent. The author has an hindex of 47, co-authored 95 publications receiving 7982 citations. Previous affiliations of Drosos E. Karageorgopoulos include Royal Free London NHS Foundation Trust & Yahoo!.
Papers
More filters
Journal ArticleDOI
Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review
Matthew E. Falagas,Matthew E. Falagas,Antonia C. Kastoris,Anastasios Kapaskelis,Drosos E. Karageorgopoulos +4 more
TL;DR: Initial clinical data support the use of fosfomycin for the treatment of urinary tract infections caused by members of the family Enterobacteriaceae with advanced resistance to antimicrobial drugs, although further research is needed.
Journal ArticleDOI
β-D-Glucan Assay for the Diagnosis of Invasive Fungal Infections: A Meta-analysis
Drosos E. Karageorgopoulos,Evridiki K. Vouloumanou,Fotinie Ntziora,Argyris Michalopoulos,Petros I. Rafailidis,Matthew E. Falagas,Matthew E. Falagas +6 more
TL;DR: BDG has good diagnostic accuracy for distinguishing proven or probable IFIs from no IFIs, and can be useful in clinical practice, if implemented in the proper setting and interpreted after consideration of its limitations.
Journal ArticleDOI
Comparison of SCImago journal rank indicator with journal impact factor
TL;DR: Although further validation is warranted, the novel SJR indicator poses as a serious alternative to the well‐established journal IF, mainly due to its openaccess nature, larger source database, and assessment of the quality of citations.
Journal ArticleDOI
Deaths attributable to carbapenem-resistant Enterobacteriaceae infections.
Matthew E. Falagas,Giannoula S. Tansarli,Drosos E. Karageorgopoulos,Konstantinos Z. Vardakas +3 more
TL;DR: In 7 studies, mortality rates ranged from 26% to 44%; in 2 studies, rates were −3% and −4%, respectively.
Journal ArticleDOI
Current control and treatment of multidrug-resistant Acinetobacter baumannii infections
TL;DR: Clinical reports support their effectiveness and mitigate previous concerns for toxicity, and several issues regarding the optimum therapeutic choices for multidrug-resistant A baumannii infections need to be clarified by future research.